同種骨髄移植と同種末梢血幹細胞移植(<特集>ドナーアフェレシスの現状と展開)
スポンサーリンク
概要
- 論文の詳細を見る
Allogeneic peripheral blood stem cell transplantation (allo-PBSCT) has been increasingly used as an alternative to allogeneic bone marrow transplantation (allo-BMT). Allo-PBSCT is associated with rapid hematopoietic recovery, increased incidence and severity of chronic graft-versus-host disease (GVHD), and possible increased incidence and severity of acute GVHD. Several prospective randomized controlled trials conducted in Western countries have shown survival benefit of allo-PBSCT in patients with advanced leukemia compared with allo-BMT. However, this survival benefit of allo-PBSCT is not confirmed in Japan. The role of allo-PBSCT relative to allo-BMT remains to be clarified, and prospective randomized trials are necessary to elucidate the advantages and disadvantages of allo-PBSCT in comparison with allo-BMT.
- 2012-10-31
著者
関連論文
- 一目瞭然!目で診る症例
- 同種骨髄移植と同種末梢血幹細胞移植(ドナーアフェレシスの現状と展開)
- HLA半合致移植後に発症した Mucor indicus による致死的接合菌症
- 急性骨髄性白血病に合併し, 血中プロカルシトニンが高値を示したアメーバ性大腸炎・肝膿瘍